Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis haemorrhagic20.03.02.0030.000533%Not Available
Deafness04.02.01.0010.002664%Not Available
Death08.04.01.0010.081105%
Decubitus ulcer23.03.11.0060.001066%Not Available
Dehydration14.05.05.0010.041827%
Delusion19.10.01.001--
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.0020.005595%Not Available
Dermatitis acneiform23.02.01.0040.001066%
Dermatitis bullous23.03.01.0020.003730%
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.001066%
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.0010.002131%Not Available
Developmental delay08.01.03.037--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000799%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.001--Not Available
Diarrhoea07.02.01.0010.252558%
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.001066%Not Available
Diplopia17.17.01.005; 06.02.06.0020.002131%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001042%
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.0050.000533%Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.0010.003730%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 35 Pages